Chemotherapy

Chemotherapy 2006;52:285–287 DOI: 10.1159/000095959 Received: October 18, 2004 Accepted after revision: September 5, 2005 Published online: September 27, 2006

Synergism of CAY-1 with Amphotericin B and Itraconazole

A.J. De Lucca^a J.M. Bland^a S. Boue^a C.B. Vigo^a T.E. Cleveland^a T.J. Walsh^b

^a Southern Regional Research Center, Agricultural Research Service, United States Department of Agriculture, New Orleans, La., and ^b Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Md., USA

Key Words

Saponin \cdot Synergism \cdot Amphotericin B \cdot Itraconazole \cdot Additive-synergistic effect

Abstract

Background: CAY-1 is a fungicidal saponin from cayenne pepper whose mode of action differs from amphotericin B (AB) and itraconazole (IT). This work determined CAY-1 synergism with AB or IT. Methods: CAY-1 was purified and used in checkerboard microdilution studies where CAY-1 and AB or IT were mixed with nongerminated (NG) and germinating (G) conidia of three Aspergillus species and Candida albicans. Inhibition was visually determined at 24 and 48 h. Results: CAY-1 had predominantly additive-synergistic interaction with AB or IT against the Aspergillus NG and G conidia. Excellent synergy between CAY-1 and AB occurred at 24 and 48 h against C. albicans. Results suggest CAY-1 enhances AB and IT efficacy.

Copyright © 2006 S. Karger AG, Basel

Presented at the 1st World Conference on Magic Bullets – Ehrlich 2004, Nürnberg, Germany, September 9–11, 2004.

Introduction

Discovery of novel, safe and effective antifungal drugs with novel modes of action is needed since extensive use of antifungal drugs has caused the emergence of resistant pathogens such as Candida [1, 2]. In addition, antifungal drugs can cause toxic or adverse drug reactions. For example, the polyene antifungal, amphotericin B (AB), has a broad range of activity but is limited in its use due to numerous adverse effects [3]. Saponins have surface-active properties which cause pores to form in microbial membranes leading to lysis, a mode of action which differs from those of AB or itraconazole (IT), an azole antifungal drug. CAY-1 is a fungicidal saponin (molecular weight 1,243 Da) present in the Capsicum frutescens fruit [4]. This work investigated potential in vitro synergism between CAY-1 and AB or IT at 24 and 48 h against nongerminated (NG) and germinating (G) conidia of several Aspergillus species and Candida albicans.

Materials and Methods

Purification of CAY-1

Aqueous extracts of cayenne pepper were freeze-dried then dissolved in deionized water (10% of the original volume) and added to a 400-gram preparative C_{18} column, 125 A, 55–105 μ m (Waters

KARGER

© 2006 S. Karger AG, Basel

Fax +41 61 306 12 34 E-Mail karger@karger.ch www.karger.com

Accessible online at: www.karger.com/che

A.J. De Lucca Southern Regional Research Center USDA, ARS, 1100 Robert E. Lee Blvd. New Orleans, LA 70124 (USA) Tel. +1 504 286 4253, Fax +1 504 286 4419, E-Mail adelucca@srrc.ars.usda.gov

Table 1. Synergism of CAY-1 with AB or IT against NG or G conidia of *Aspergillus* species and *C. albicans*

Fungus Cotyp A. flavus NC A. flavus NC A. flavus G A. flavus G A. flavus G A. flavus NC A. flavus	e t	24 48	combination CAY-1 + AB	0.60
A. flavus NC A. flavus G A. flavus G A. flavus G	} 4	48		
A. flavus G A. flavus G	2		CAY-1 + AB	
A. flavus G				2.00
)		24	CAY-1 + AB	1.50
A. flavus NC	2	48	CAY-1 + AB	1.38
	j 2	24	CAY-1 + IT	0.89
A. flavus NC	j 4	48	CAY-1 + IT	0.88
A. flavus G	2	24	CAY-1 + IT	1.50
A. flavus G	2	48	CAY-1 + IT	1.25
A. fumigatus NC	j 2	24	CAY-1 + AB	0.78
A. fumigatus NC	j 4	48	CAY-1 + AB	0.82
A. fumigatus G	2	24	CAY-1 + AB	0.66
A. fumigatus G	2	48	CAY-1 + AB	0.74
A. fumigatus NC	3	24	CAY-1 + IT	0.89
A. fumigatus NC	}	48	CAY-1 + IT	0.64
A. fumigatus G	2	24	CAY-1 + IT	0.66
A. fumigatus G	4	48	CAY-1 + IT	0.86
A. niger NC	} 2	24	CAY-1 + AB	0.81
A. niger NC	}	48	CAY-1 + AB	2.00
A. niger G	2	24	CAY-1 + AB	0.91
A. niger G	2	48	CAY-1 + AB	0.99
A. niger NC	3	24	CAY-1 + IT	0.83
A. niger NC	}	48	CAY-1 + IT	0.66
A. niger G	2	24	CAY-1 + IT	0.83
A. niger G	4	48	CAY-1 + IT	0.58
C. albicans	2	24	CAY-1 + AB	0.22
C. albicans	4	48	CAY-1 + AB	0.32
C. albicans	2	24	CAY-1 + IT	2.0
C. albicans	2	48	CAY-1 + IT	2.0

Corp., Millford, Mass., USA) and eluted with a methanol (MeOH) step gradient [4]. CAY-1 was in the 75% MeOH eluate. MeOH was evaporated and the remaining liquid freeze-dried. CAY-1 was purified by reverse-phase high performance liquid chromatography using a Waters (Millford, Mass., USA) 25 \times 100 mm C_{18} RCM column on an Applied Biosystems BioCad 700E (Foster City, Calif., USA). CAY-1 was detected by mass spectroscopy and lethality bioassays with *Aspergillus flavus* [1]. CAY-1 purity was confirmed by liquid chromatography and mass spectroscopy.

Checkerboard Microdilution Inhibition Studies

Synergy was measured by the checkerboard method [5]. AB or IT was diluted (1:2) along the rows of a sterile 96-well microtiter plate while CAY-1 was diluted (1:2) along the columns. NG and G conidia of *A. flavus, A. fumigatus,* and *A. niger* were separately tested in three separate runs per sample type. *C. albicans* was similarly tested. Fungal stock suspensions were adjusted to 10^2 conidia/well. Assays for all fungi but *A. niger* were performed in RPMI-1640 since earlier work showed CAY-1 was effective against *A. niger* only in 1% PDB [1]. End points were determined visually as the well having the lowest concentration of compounds with an absence of growth at 24 and 48 h. Results were expressed as the fractional

inhibitory concentration index (FICI) [6]. FICIs of \leq 0.5, 1.0, and >4.0 were considered indicative of synergy, additive activity, and antagonism, respectively.

Results

CAY-1 showed predominantly additive-synergistic interaction with AB or IT against the NG and G conidia of the tested *Aspergillus* species (table 1). CAY-1, at 24 and 48 h, enhanced AB activity against both the NG and G conidia of *A. fumigatus* and *A. niger* at the additive-synergy level. Less synergistic-additive interaction occurred against *A. flavus* where the predominant effect was indifferent. Excellent synergy between CAY-1 and AB occurred at 24 and 48 h against *C. albicans*. CAY-1 interacted indifferently with IT against *C. albicans*.

Discussion

CAY-1 was synergistic in vitro with both AB and IT against the NG and G conidia of the tested *Aspergillus* species at 24 and 48 h and was synergistic with AB, but not with IT, against *C. albicans*. AB interacts with ergosterol which causes increased membrane permeability for cations and cell death [7]. IT, a triazole, inhibits ergos-

terol synthesis which disrupts fungal membrane development [7] while saponins (e.g. CAY-1) affect membrane integrity. Combinations of antifungal compounds having differing modes of action could improve the likelihood of effective treatment of mycoses and reduce the risk of resistance in the target organism. Results indicate CAY-1 may enhance the efficacy of azole and polyene antifungals.

References

- 1 Alexander BD, Perfect JR: Antifungal resistance trends towards the year 2000 Implications for therapy and new approaches. Drugs 1997:54:657–678.
- 2 Boschman CR, Bodnar UR, Tornatore MA, Obias AA, Noskin GA, Englund K, Postelnick MA, Suriano T, Peterson LR: Thirteen-year evolution of azole resistance in yeast isolates and prevalence of resistant strains carried by cancer patients at a large medical center. Antimicrob Agents Chemother 1998;42:734–738.
- 3 De Pauw BE, Meunier F: The challenge of invasive fungal infection. Chemother 1999; 45(suppl 1):1–14.
- 4 De Lucca AJ, Bland JM, Vigo CB, Cushion M, Selitrennikoff CP, Peter J, Walsh TJ: CAY-1, a fungicidal saponin from *Capsicum* sp. Fruit Med Mycol 2002;40:131–137.
- 5 Amsterdam D: Susceptibility testing of antimicrobials in liquid media; in Lorian V (ed): Antibiotics in Laboratory Medicine, ed 4. Baltimore, Williams and Wilkins, 1996, pp 52–111.
- 6 Yan H, Hancock RE: Synergistic interactions between mammalian antimicrobial defense peptides. Antimicrob Agents Chemother 2001; 45:1558–1560.
- 7 Groll AH, De Lucca AJ, Walsh TJ: Emerging targets for the development of novel antifungal therapeutics. Trends Microbiol 1998;6:117– 124.